APA
Click to copy
Ou, Y.-C., Wen, X., Johnson, C. A., Shae, D., Ayala, O., Webb, J., … Bardhan, R. (2019). Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano.
Chicago/Turabian
Click to copy
Ou, Yu-Chuan, Xiaona Wen, Christopher A. Johnson, Daniel Shae, O. Ayala, J. Webb, Eugene C. Lin, et al. “Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.” ACS nano (2019).
MLA
Click to copy
Ou, Yu-Chuan, et al. “Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.” ACS Nano, 2019.
BibTeX Click to copy
@article{yu-chuan2019a,
title = {Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.},
year = {2019},
journal = {ACS nano},
author = {Ou, Yu-Chuan and Wen, Xiaona and Johnson, Christopher A. and Shae, Daniel and Ayala, O. and Webb, J. and Lin, Eugene C. and Delapp, Rossane C. and Boyd, K. and Richmond, A. and Mahadevan-Jansen, A. and Rafat, M. and Wilson, John T. and Balko, J. and Tantawy, M. and Vilgelm, A. and Bardhan, R.}
}
The overexpression of immunomarker programmed cell death protein 1 (PD-1) and engagement of PD-1 to its ligand, PD-L1, is involved in the functional impairment of cluster of differentiation 8 (CD8) T cells contributing to cancer progression. However, heterogeneities in PD-L1 expression and variabilities in biopsy-based assays render current approaches inaccurate in predicting PD-L1 status. Therefore, PD-L1 screening alone is not predictive of patient response to treatment, which motivates us to simultaneously detect multiple immunomarkers engaged in immune modulation. Here, we have developed a multimodal probe, immunoactive gold nanostars (IGNs), that accurately detects PD-L1+ tumor cells and CD8+ T cells simultaneously in vivo, surpassing the limitations of current immunoimaging techniques. IGNs integrate the whole-body imaging of positron emission tomography with high sensitivity and multiplexing of Raman spectroscopy, enabling the dynamic tracking of both immunomarkers. IGNs also monitor response to immunotherapies in mice treated with combinatorial PD-L1 and CD137 agonists, and distinguish responders from those nonresponsive to treatment. Our results showed a multifunctional nanoscale probe with capabilities that cannot be achieved with either modalities alone, allowing multiplexed immunologic tumor profiling critical for predicting early response to immunotherapies.
